Compare ACRS & MTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | MTW |
|---|---|---|
| Founded | 2012 | 1902 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 749.4M |
| IPO Year | 2015 | 1994 |
| Metric | ACRS | MTW |
|---|---|---|
| Price | $3.90 | $21.25 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 12 | 2 |
| Target Price | $10.18 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 3.6M | 423.0K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | $1,683,000.00 | ★ $2,240,900,000.00 |
| Revenue This Year | N/A | $3.43 |
| Revenue Next Year | N/A | $1.55 |
| P/E Ratio | ★ N/A | $98.73 |
| Revenue Growth | N/A | ★ 2.89 |
| 52 Week Low | $1.74 | $9.93 |
| 52 Week High | $6.60 | $24.00 |
| Indicator | ACRS | MTW |
|---|---|---|
| Relative Strength Index (RSI) | 33.30 | 48.05 |
| Support Level | $3.16 | $21.14 |
| Resistance Level | $4.63 | $21.42 |
| Average True Range (ATR) | 0.41 | 0.96 |
| MACD | -0.15 | -0.24 |
| Stochastic Oscillator | 28.38 | 2.26 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Manitowoc Co Inc provides engineered lifting solutions. It designs and manufactures mobile telescopic cranes, tower cranes, lattice-boom crawler cranes, and boom trucks. It offers products under brand names such as Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Manitowoc Crane Care. Its crane products serve dealers, rental companies, contractors, and government entities in diverse markets, including energy production/distribution and utility, petrochemical and industrial, infrastructure, and commercial/residential construction. Manitowoc has three reportable segments: the Americas, Europe and Africa, and the Middle East and Asia-Pacific. The Americas segment generates the majority of the revenue for the company.